Contrast media

Product Details:

Clariscan™ (gadoterate meglumine) injection for intravenous use
Clariscan™ ( gadoterate meglumine) is a macrocyclic gadolinium-based contrast agent, expertly manufactured by GE HealthCare, used to enhance visualization in MRI procedures across a range of indicationsABOUT CLARISCAN
As part of our comprehensive MR product portfolio, GE HealthCare is proud to offer Clariscan (gadoterate meglumine), the generic equivalent of Dotarem®. Clariscan is a macrocyclic, general-purpose GBCA used to enhance over 20 million MRI procedures globally since launch.
Clariscan is available in a range of packaging options, has a well-established tolerability profile, and is manufactured in-house by GE HealthCare. Enhanced confidence in continuity of supply and in product availability is further supported by GE HealthCare’s vertically integrated Clariscan manufacturing process.Gadoterate Meglumine: the only macrocylic, ionic molecule
Stability refers to how tightly the gadolinium ion is bound to the chelating molecule and how likely it is to dissociate. Gadoterate meglumine is the only macrocyclic, ionic molecule across all gadoliunium-based contrast agents. In vitro data suggest that combining a macrocyclic structure for high kinetic stability, with ionicity for thermodynamic stability, may help to reduce the potential risk of gadolinium dissociation.1

Product Details:

Composition :
Diatrizoate sodium salt......41.7% w/v (Diatrizoic Acid USP With sodium hydroxide IP )
In a flavoured aqueous Base.....q.s.
Iodine Content.........249.64 mg/ml
Colour : Sunset yellow FCF
INDICATIONS:
Visualization of the gastro-intestinal tract.
Early diagnosis of a radiologically undetectable perforation or anastomatic defect in the oesophagus or gasrointestinal tract.
For computerized Tomography(CT) in the abdominal region.
For ORAL use only.....not for parenteral use.

Product Details:

Visipaque™ (Iodixanol) Injection
Visipaque™ (iodixanol) injection - the only contrast media for intravascular use that is iso-osmolar to blood and isotonic at all concentrations in the US
Visipaque: Prepared for high risk patients
More than 1 in 7 adults in the US are estimated to have CKD, and most don't know it.³ 34.2 million Americans - just over 1 in 10 - have diabetes.⁴ By 2060, 1 in 4 people in the US will be aged 65+, with the number over 85 years expected to nearly triple.⁵
Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in high risk patients should be considered to help mitigate the risk of adverse events.⁶ Visipaque, an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures, was prepared with this in mind.
FEATURES
Your choice of iodinated contrast media could help mitigate adverse events
Interventional, structural, or endovascular procedures (e.g., TAVI, CTO, PCI) may need to use higher volumes of iodinated CM. Reducing the frequency of adverse reactions has therefore been a driving force in the development of these diagnostic agents since their initial introduction
SAFETY
High risk patient populations are ever growing^8,9
Visipaque is a third-generation agent with a unique molecular structure developed to further improve the safety profile of iodinated contrast agents.^8,10 It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.^10,11 It is also formulated with balanced electrolytes to help minimize effects on cardiac contractile force/fibrillatory propensity.^10,11 While 'low' osmolar agents form the mainstay in the general population of patients undergoing endovascular diagnostic or interventional procedures, Visipaque may be preferred for more complex procedures in patients considered at high risk for cardiovascular or renal insult.^1,8
VALUE
Can help reduce cost by helping to reduce risk
When compared to total interventional procedure cost, contrast media is inexpensive but CA-AKI and contrast media-related adverse events may increase the use of health care resources and cost of care.¹⁵ Given the growth of vulnerable patient populations, practices that reduce CA-AKI incidence and its associated costs are important to identify.²
According to a study conducted to determine the net economic impact of switching from low-osmolar contrast media (LOCM) to iso-osmolar contrast media (IOCM; iodixanol) in patients undergoing inpatient coronary or peripheral angioplasty in the US, moving on to an IOCM-only strategy may yield substantial cost savings to US hospitals where coronary and peripheral procedures are performed.²
REDUCE PATIENT DISCOMFORT
Increased patient comfort can help improve throughput
Enhancing interventional radiology procedural comfort is important for both patients and efficiency, as movement may necessitate studies being repeated or prolonged.^29-31
A benefit of iso-osmolar Visipaque is the reduction

Product Details:

Iohexol injection is used to help diagnose or find problems in the brain, back, heart, head, blood vessels, stomach, joints, pancreas, bladder, reproductive tract, and other parts of the body. It is an iodinated contrast agent. Contrast agents are used to create a clear picture of the different parts of the body during certain medical procedures (eg, CT scans).

Product Details:

Iomeron®
Iomeron® is a tri-iodinated non-ionic monomeric contrast medium for radiology7
When highest iodine concentration matters1,2,3,4,5,6Iomeron® has interesting favorable properties, such as
the lowest viscosity at given concentration among iso-osmolar contrast media (IOCM) and low-osmolar contrast media (LOCM)7;
the lowest osmolality among monomeric LOCM7;
one formulation with the highest iodine concentration (400 mgI/mL) available on the market.
An injectable solution at a higher iodine concentration allows a greater peak of enhancement in a shorter time from the injection when injected at the same volume and flow rate compared to a solution at a lower iodine concentration8.
Iomeron® (Iomeprol) is Bracco's latest generation contrast agent. Launched in 19959, this tri-iodinated non-ionic contrast agent has quickly become the preferred choice for many practicing clinicians9. Its unique and innovative profile can boast the highest concentration (400 mgI/mL), nonionic agent ever approved in the world10.
Iomeprol is currently registered in more than 40 countries worldwide, including all major European & Middle Eastern countries, Japan and the Asian Pacific. This agent represents a step forward in its class. Iomeprol has become the number one choice for many clinicians for many reasons – including:
a unique product that combines the lowest viscosity among non-ionic agents and a very low osmolality compared to other available nonionic monomeric agents10;
Iomeron® is readily available in a wide variety of iodine concentration and volumes for clinical use;
in first pass dynamic CT imaging, at equal flow rate and total iodine dose, Iomeprol 400 mgI/mL, can provide better contrast enhancement and image quality than contrast solutions at lower iodine strength11,12,13;
in a multicenter, randomized, double-blind, parallel-group comparison of Iomeron and iodxanol in coronary CTA, observed mean heart rate changes after intravenous contrast injection were generally small during the examination and comparable for Iomeron-400 and iodixanol 32014;
a prospective intra-individual study showed that a low-dose radiation exposure acquisition protocol, in conjunction with the use of Iomeron-400, provides substantially reduced radiation exposure while maintaining a constant CNR and good image quality compared to a standard protocol using a lower concentrated contrast medium in CTA examinations15;
a large study compared the effects of Iomeprol-400 and Iodixanol-320 on kidney function in patients with pre-existing chronic kidney diseases (CKD) undergoing CT examinations. Based on the results, the authors of the study concluded: "The incidence of CIN was significantly higher after the IV administration of iodixanol-320 than iomeprol-400 in patients with moderate-to-severe CKD. The mean increase in SCr from baseline was also higher in patients receiving iodixanol. Characteristics of the individual contrast agents other than osmolality may be important in causing nephrotoxicity" 16.

Product Details:

Jai Mata Dee Enterprises was incorporated in the year 2012 as Sole Proprietorship based firm. We are the prestigious Wholesale Trader of X-Ray Film, Pathological Products, Surgical Goods, Diagnostic Equipment and Machines, Vaccine and Total Medical Solution, etc. All our team members actively strive to meet the diverse requirements of our clients so as to achieve maximum customer satisfaction. Moreover, our products are available at industry leading prices. We possess a spacious warehouse for the safe storage of these products. Our transparent business policies have helped us in garnering a huge client base in the market.

Product Details:

Gadobenate dimeglumine (trade name MultiHance) is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance the visualization of certain tissues and organs. It's particularly effective for liver imaging due to its hepatobiliary excretion and ability to enhance liver tissue. It is also used for visualizing blood vessels in the brain, spine, and associated tissues. 
Elaboration:
How it works:
Gadobenate dimeglumine is a paramagnetic contrast agent, meaning it interacts with magnetic fields. When injected, it enhances the magnetic relaxation of nearby water molecules, leading to changes in signal intensity on MRI images. 
Hepatobiliary excretion:
Unlike many other gadolinium-based contrast agents that are primarily excreted by the kidneys, gadobenate dimeglumine is also excreted through the biliary system (bile ducts). This property makes it particularly useful for liver imaging as it allows for visualization of the liver, bile ducts, and potentially some liver lesions. 
Uses in MRI:
Liver imaging: Gadobenate dimeglumine can help differentiate between healthy liver tissue and lesions (tumors, cysts, etc.). 
CNS (Central Nervous System) imaging: It is used to visualize blood vessels in the brain and spine, which can help in diagnosing conditions like stroke or aneurysms. 
Safety:
Gadobenate dimeglumine is generally well-tolerated, but potential side effects can include mild reactions at the injection site, nausea, or headache. There is a rare risk of kidney damage, particularly in individuals with existing kidney problems. 
Dosage:
The recommended dose of gadobenate dimeglumine for MRI of the CNS is 0.2 mL/kg in adults and pediatric patients over 2 years old, administered as a rapid bolus intravenous injection. A saline flush is recommended after the injection to ensure complete injection of the contrast medium.

Product Details:

Product Details:

Product Details:

Product Details: